Tumor necrosis after preventive embolization of large renal angiomyolipomas  by El Rafei, M. et al.
Diagnostic and Interventional Imaging (2015) 96, 579—587
ORIGINAL ARTICLE /Genito-urinary imaging
Tumor  necrosis  after  preventive
embolization  of  large  renal
angiomyolipomas
M.  El  Rafeia,  B.  Renarda,  P.  Puecha,b,  P.  Devosc,
V.  Gaillarda,  L.  Lemaîtrea,b,∗
a Service  d’imagerie  néphro-urologique  et  ORL,  université  Lille,  hôpital  Claude-Huriez,  CHRU
de Lille,  1,  rue  Michel-Polonovski,  59037  Lille  cedex,  France
b Inserm  U703,  université  Lille  Nord  de  France,  CHRU  de  Lille,  59120  Loos,  France
c Délégation  à  recherche  clinique  et  à  l’innovation,  université  Lille  Nord  de  France,  CHRU  de
Lille, 59000  Lille,  France
KEYWORDS
Angiomyolipoma;
Embolization;
Preventive;
Necrosis
Abstract
Objectives:  The  purpose  of  this  study  was  to  retrospectively  evaluate  tumor  necrosis  following
preventive  embolization  in  patients  with  renal  angiomyolipoma  (RAML)  at  high  risk  of  bleeding.
Patients and  methods:  Arterial  embolization  was  performed  in  24  patients  (22  women,  2  men;
mean age,  43  ±  13  years)  with  a  total  of  30  RAMLs  (mean  volume,  137  cm3 ±  163)  between
1996 and  2012.  Two  sub-groups  of  patients  were  identiﬁed  and  further  compared  based  on  the
presence  or  not  of  necrosis  following  arterial  embolization.
Results:  The  technical  and  clinical  success  rates  of  arterial  embolization  of  RAMLs  were  97%
and 87%,  respectively.  The  mean  initial  volume  of  RAMLs  differed  between  the  two  sub-groups
with 331  cm3 in  the  group  with  tumor  necrosis  and  88  cm3 in  the  group  without  tumor  necrosis
(P =  0.0047).  High-fat  content  RAMLs  were  predominantly  observed  in  the  necrosis  group  and
the mean  volume  reduction  observed  for  high-fat  RAMLs  was  65%  whereas  it  was  36%  for  low-fat
content RAMLs.  The  six  patients  who  developed  RAML  necrosis  had  arterial  embolization  using
microspheres  (one  patient  with  microspheres  alone  and  ﬁve  with  a  combination  of  microspheres
and metallic  coils).  All  necrotic  RAMLs  displayed  arterial  dysplasia.
Conclusion:  The  risk  of  tumor  necrosis  is  higher  for  larger  RAMLs.  The  role  of  distal  arterial
embolization  with  microspheres  in  tumor  necrosis  in  RAML  is  suggested  by  the  results  of  our
study but  could  not  be  deﬁnitely  demonstrated  statistically  due  to  the  limited  sample  size.© 2015  Published  by  Elsevier  Ma
Abbreviations: RAML, renal angiomyolipoma; TSC, tuberous sclerosis
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ntroduction
enal  angiomyolipomas  (RAMLs)  are  hypervascular  benign
umors  that  convey  a  risk  for  hemorrhagic  complications.
hey  occur  sporadically  in  80%  of  patients  or  for  the
emaining  in  patients  with  tuberous  sclerosis  complex  (TSC,
0%).  In  most  cases,  AMLs  show  tissue  heterogeneity  (vascu-
ar,  adipose  and  muscle  tissue)  [1—7].  This  category  of  lesion
s  rare,  representing  1%  of  renal  tumors,  with  an  incidence
anging  from  0.07  to  0.3%  [8,9].
The  treatment  of  acute  bleeding  due  to  rupture  of  RAML
s  well  established  depending  on  the  patient’s  hemodynamic
tatus.  Arterial  embolization  is  currently  used  as  the  favored
ethod  [10—12].
However,  no  clear  consensus  has  been  reached  on  when
nd  how  to  apply  preventive  treatment.  The  use  of  thera-
eutic  arterial  embolization  is  debated,  depending  on  the
isk  of  hemorrhage  using  criteria  described  in  previous
eports:  tumor  size  >  4  cm,  aneurysm  >  4—5  mm,  history  of
inor  RAML  bleeding  [6,11,13].  When  preventive  treatment
s  indicated,  surgery  can  be  a  valid  approach  if  emboliza-
ion  fails  or  in  some  speciﬁc  cases  (isolated  RAML,  RAML
ith  a  large  exorenal  component,  foreseeable  difﬁculties
n  post-embolization  follow-up)  [14,15].
Several  studies  have  demonstrated  the  technical  and
linical  efﬁciency  of  hemostatic  and  preventive  arterial
mbolization  [16—18].  Complications  occurring  after  pre-
entive  arterial  embolization,  such  as  tumor  necrosis,  are
enerally  rare  [10].
The  purpose  of  the  present  study  was  to  describe  the
linical,  biological  and  imaging  features  of  the  main  compli-
ation  (i.e.,  tumor  necrosis,  as  deﬁned  by  lipid  necrosis  of
he  entire  RAML)  and  to  assess  the  risk  factors  involved  in
ts  occurrence.
atients and methods
his  retrospective  single-center  study  covered  a period
f  16  years  (from  1996  to  2012)  and  included  33
atients  who  underwent  RAML  embolization  because  of
 potential  risk  of  hemorrhagic  complications  (tumor
ize  >  4  cm,  aneurysm  >  4—5  mm,  history  of  minor  AML
leeding).  Only  patients  fulﬁlling  the  inclusion  criteria
T
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Table  1  Descriptive  statistics  and  RAML  characteristics  of  the
Population  Overall  popu
Number  of  patients  (n  [%])  24  
Mean  age  (years)  43  ±  13  
Male  (n  [%])  2  (8)  
Female  (n  [%])  22  (92)  
Sporadic  RAML  (n  [%])  15  (63)  
Congenital  TSC  lesions  (n  [%])  9  (37)  
Number  of  RAMLs  (n  [%]) 30  
Mean  initial  volume  of  RAML  (cm3)  137  ±  163  
Mean  aneurysm  size  (mm) 4.7  ±  5.8  
Presence  of  arterial  dysplasia  (n  [%]) 25  (83)
Number  of  predominantly  fatty  RAMLs  >  50%  (%)  24  (80)  
Number  of  RAMLs  with  aneurysm  (%)  14  (47)  M.  El  Rafei  et  al.
or  preventive  arterial  embolization  were  included;  nine
atients  were  excluded  following  emergency  arterial
mbolization  due  to  active  bleeding  with  hemorrhagic
hock.
Two  patient  sub-groups  were  identiﬁed  following  data
ollection  based  on  the  presence  or  not  of  post-embolization
ecrosis  (Table  1).  Creatinine  clearance  levels  were  evalu-
ted  prior  to  arterial  embolization.
maging ﬁndings
iagnosis  of  RAML  was  based  on  the  presence  of  intratumoral
acroscopic  fat  with  a  spontaneous  attenuation  value  of  less
han  −20  HU  on  computed  tomography  (CT).
The  fatty  component  was  considered  to  be  predomi-
ant  if  an  attenuation  value  <  −20  HU  was  found  in  more
han  50%  of  the  tumor  volume  with  only  attenuation  val-
es  < −20  HU.  This  50%  threshold  was  proposed  by  Planché
t  al.  [19].
Clinical,  biological  and  radiological  follow-up  was  per-
ormed  either  by  abdominal  CT  scans,  or  by  a  combination
f  CT  scans  and  renal  MR  imaging  examinations.  Follow-up
isits  were  scheduled  six  months  after  arterial  embolization
nd  then  every  two  years.  Patients  in  the  necrosis  group
ere  monitored  more  regularly  during  the  ﬁrst  year  after
mbolization.
elective embolization
enal  angiograms  were  ﬁrst  obtained  via  a  puncture  of
he  femoral  artery  using  a  4-  or  5-Fr  introducer  sheath.
he  aim  was  to  achieve  selective  catheterization  in  order
o  preserve  the  maximum  volume  of  the  normal  renal
arenchyma.
Embolic  agents  consisted  of  microspheres,  coils  or  a  com-
ination  of  metallic  coils  and  microspheres.
ost-embolization assessmenthe  success  of  arterial  embolization  was  assessed  imme-
iately  using  angiography  and  considered  successful  if  the
umor  vascular  network,  intratumoral  aneurysms  and  arte-
ial  dysplasia  were  no  longer  visible.
 study  population.
lation  Patients  without  necrosis  Patients  with  necrosis
18  (75)  6  (25)
45  ±  15  41.5  ±  9.6
2  (11)  0  (0)
16  (89)  6  (100)
11  (61)  4  (67)
7  (39)  2  (33)
24  (80)  6  (20)
88  ±  94  331  ±  240
9.1  ±  6.1  2.1  ±  2.5
19  (79)  (median  5)  6  (100)  (median  25)
18  (75)  (median  6)  6  (100)  (median  24)
11  (46)  (median  16)  3  (50)  (median  14)
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Pre-  and  post-embolization  RAML  volumes  were  calcu-
lated  using  the  ellipsoid  formula  in  all  three  planes  (one  half
the  product  of  the  three  dimensions);  the  maximum  change
in  volume  was  calculated  using  the  last  tumor  measurements
available  on  CT  data.
Embolization  procedures  and  data  on  the  variation  of
RAML  volume  were  reviewed  for  the  whole  study  popula-
tion,  and  then  by  subgroup  (RAMLs  treated  with  both  coils
and  microspheres,  with  microspheres  alone,  and  with  coils
alone).  RAML  volume  variation  was  also  analyzed  depending
on  RAML  fat  content  (over  or  under  50%)  and  the  occurrence
of  post-embolization  necrosis  (Table  2).
Any  post-embolization  complications  (Table  3)  were
recorded  and  classed  based  on  the  time  of  occurrence  (post-
embolization  syndrome,  late  tumor  necrosis,  early  and  late
complications).
Statistical analysis
Statistical  analysis  was  performed  using  SAS® v9.3  soft-
ware  (Cary,  NC,  USA).  Continuous  variables  were  described
as  medians,  means  and  standard  deviations  (SD).  Com-
parisons  were  performed  using  Chi2 test  or  Fisher’s  exact
test.  Binary  variables  were  described  as  raw  numbers,  pro-
portions  and  frequencies.  Comparison  between  the  two
subgroups  of  patients  (depending  on  the  presence  of  necro-
sis  in  RAML  after  arterial  embolization)  was  performed  using
the  Wilcoxon  test.
p
t
Table  2 Embolic  agents,  reduction  in  RAML  volume  depending
Population  Over
popu
Number  of  RAMLs  (%) 30 
Distal  embolization  (microspheres)  (n  [%]) 22 (7
Proximal  vessel  occlusion  (coils)  (n  [%]) 27  (9
Embolization  with  microspheres  and  coils  (n
[%])
18  (6
Embolization  with  microspheres  alone  (n
[%])
4 (13
Embolization  with  coils  alone  (n  [%])  8  (27
Number  of  successful  procedures  as
assessed  by  angiography  (%)
29 (9
Mean  duration  of  follow-up  (months)  42  ±  
Mean  reduction  in  RAML  volume  (%)  60  
Mean  reduction  in  RAML  volume  (%)  for
each  embolic  agent
Coils  +  micropheres  68  
Microspheres  alone  (n  [%])  1:  50
1: 12
1: 99
1: inc
Coils  alone  (%)  37  
Mean  reduction  in  tumor  volume  (%)
depending  on  fat  content
fat  <  50%  36  
fat  >  50%  65  
Number  of  re-embolization  procedures  (%)  4  (13
Partial  nephrectomy  (n  [%])  1  (3)omyolipomas  581
esults
escriptive  statistics  and  tumor  characteristics  are  provided
n  Table  1  for  the  overall  population  and  the  two  sub-groups.
Twenty-four  patients  (22  women  and  2  men)  with  a  mean
ge  of  43  ±  13  years  (range:  15—77—years)  were  included  in
he  study.  They  had  a  total  of  30  embolized  RAMLs.
RAMLs  were  sporadic  in  15/24  patients  (63%;  of  them
2  patients  had  a  single  RAML)  or  associated  with  tuberous
clerosis  complex  in  9/24  patients  (37%)  (all  with  multiple
AMLs).  A  single  RAML  was  present  in  11/24  patients  (46%)
nd  13/24  patients  (54%)  had  multiple  RAMLs.
Twelve  RAMLs  were  detected  incidentally  in  the  absence
f  bleeding.  Eighteen  RAMLs  (60%)  were  diagnosed  follow-
ng  lower  back  pain  due  to  intratumoral  hematoma  or  minor
ntreated  hematoma  (n  =  11/18),  including  two  pregnant
omen  with  light  bleeding.
Prior  to  treatment,  the  mean  RAML  size  was  7  ±  3  cm
range:  4—16  cm)  and  the  mean  pre-embolization  vol-
me  was  137  cm3 (6—612  cm3).  Twenty-seven  RAMLs  (90%)
ere  >  4  cm,  14  (47%)  showed  one  or  more  aneurysms  >  4  mm
as  deﬁned  by  the  longest  axis  measured  on  CT  scan)  with  a
ean  aneurysm  size  of  4.7  mm  (ranging  from  4  to  25  mm),
5  (83%)  displayed  arterial  dysplasia  and  24  RAML  (80%)  had
 fat  content  >  50%.
Renal  function  prior  to  embolization  was  normal  for  all
atients,  as  estimated  by  creatinine  clearance  levels.
A  2.7  Fr  microcatheter  was  used  for  27  RAMLs  (90%  of  the
umors)  and  a  2.4  Fr  microcatheter  for  the  three  remaining
 on  the  embolic  agents  and  fat  content,  and  success  rates.
all
lation
Without
necrosis
With
necrosis
24  (80)  6  (20)
3) 16 (67)  6  (100)
0)  22  (92)  5  (83)
0) 12 (50)  5  (83)
)  3  (13)  1  (17)
)  8  (33)  0  (0)
7)  23  (96)  6  (100)
36  49  ±  36  12  ±  5
53  81
65  77
rease
31 99  (n  =  1)
37
36  —
57  81
)  4  (17)  0  (0)
 1  (4)  0  (0)
582  M.  El  Rafei  et  al.
Table  3  Main  post-embolization  complications.
Complications  Total  number  of
procedures
(n  =  30)
RAML  without
post-treatment
necrosis
(n  = 24)
RAML  with
post-treatment
necrosis
(n  =  6)
Post-embolization  syndrome  (n  [%]) 19  (63) 13  (54) 6  (100)
Biological  inﬂammatory  syndrome  (n  [%]) 7 (23) 1  (4) 6  (100)
Pyelocalyceal  compression  (n  [%])  3  (10)  0  (0)  3  (50)
Retroperitoneal  ﬂuid  collection  (n  [%])  2  (7)  0  (0)  2  (33)
Inﬂammatory  inﬁltrate  in  retroperitoneal  fat  (n  [%])  6  (20)  0  (0)  6  (100)
Arterial  hypertension  (n  [%])  1  (3)  1  (4)  0  (0)
2  (7)
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AMLs.  The  embolic  agents  used  were  microspheres  and/or
oils.  The  embolization  procedures  included  22  (73%)  distal
mbolizations  using  microspheres  with  size  ranging  from  200
o  1200  m,  and  27  (90%)  proximal  vessel  occlusions  with
oils.  Eighteen  RAMLs  (60%)  were  treated  with  a  combination
f  microspheres  and  coils,  eight  (27%)  with  coils  alone,  and
our  (13%)  with  microspheres  alone.
The  mean  duration  of  follow-up  was  42  ±  36  months  in
he  overall  population  (both  sub-groups).  Imaging  follow-up
onsisted  predominantly  of  abdominal  CT  scans  (alternating
T  scans  and  renal  MR  imaging  in  nine  patients).
uccess rate of primary embolization and
econdary treatment
he  technical  success  rate,  as  deﬁned  by  uncomplicated
rterial  embolization  and  devascularization  of  RAML  on  arte-
iogram,  was  97%  (29/30).  Embolization  was  not  achieved  in
ne  patient  due  to  arterial  spasm  during  the  procedure.
The  clinical  success  rate,  as  deﬁned  by  a  decrease  in
AML  volume  and  vascularization  (or  even  complete  dis-
ppearance  of  the  RAML  during  follow-up)  was  87%  (26/30
AMLs)  (Fig.  1).
Clinical  success  was  only  partial  in  four  patients.  Three
f  these  four  patients  were  re-embolized  due  to  an
ncrease  in  RAML  size.  The  remaining  patient  underwent
a
c
b
igure 1. a: contrast-enhanced CT scan in the coronal plane obtain
AML located in the lower pole of the left kidney (white arrow); b: con
rterial/cortical phase after arterial embolization with coils alone of 
eduction of tumor volume (black arrow). 2  (8)  0  (0)
e-embolization  for  persistent  hypervascularization  during
ollow-up.
Following  discussion  by  a  multidisciplinary  team  of
pecialists  (urologists  and  radiologists),  nephrectomy  was
erformed  in  one  patient  initially  treated  with  microspheres
nd  coils  due  to  an  increase  in  RAML  size.
No  active  bleeding  occurred  during  or  immediately  after
e-embolization  procedures.  No  cases  of  renal  failure  were
bserved  immediately  after  the  procedure  or  during  follow-
p.  Transitory  post-embolization  syndrome  with  onset  of
ever  and  pain  was  observed  in  the  days  following  the
rocedure  in  19  patients  (63%)  and  was  managed  with  an
ppropriate  analgesic  treatment  [20,21].
umor necrosis
ix  (20%)  of  the  30  embolized  RAMLs  showed  post-
mbolization  tumor  necrosis.
Tumor  necrosis,  deﬁned  as  lipid  necrosis  of  the  whole
AML,  differs  from  post-embolization  syndrome  by  its  delay
>  1  month  after  embolization)  (mean  delay  of  2.3  months:
our  months  [n  =  1],  three  months  [n  =  2],  two  months  [n  =  1]
nd  one  month  [n  =  2]).
Post-embolization  necrosis  was  characterized  by  spe-
iﬁc  clinical  and  biological  features:  chronic  diffuse  lower
ack  pain  often  described  as  a nagging  pain  or  heaviness,
ed during the arterial/cortical phase prior to embolization of an
trast-enhanced CT scan in the coronal plane obtained during the
an RAML located in the lower pole of the left kidney. Near-total
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persistent  inﬂammatory  syndrome  (average  duration  of  nine
months  ranging  from  one  month  to  18  months),  and  high  CRP
levels  without  any  signs  of  infection.
In  these  six  tumor  necrosis  cases,  very  similar  imaging
ﬁndings  were  observed:  initial  increase  in  volume  due  to
necrosis  and  the  subsequent  inﬂammatory  reaction  (peri-
renal  or  retroperitoneal),  complete  devascularization  of  the
tumor,  initial  heterogeneous  necrosis  with  air  bubbles  in  the
central  part  delimited  by  a  thick,  contrast-enhanced  wall.
This  feature  tends  to  gradually  turn  into  a  liquefactive  fatty
necrotic  layer  (‘‘fat-necrosis  level’’)  (n  =  6)  (Figs.  2  and  3).
Three  patients  showed  pyelocalicial  dilatation  due  to  peri-
renal  inﬂammation,  but  no  urinary  derivation  (stent)  was
needed  because  there  were  no  signiﬁcant  signs  of  obstruc-
tion.
Drainage  was  performed  in  two  patients  due  to  a  high  risk
of  rupture  of  the  necrotic  tumor  (retroperitoneal  compart-
ment  extension  and  poor  inﬂammatory  clinical  tolerance).
One  case  was  managed  surgically  (heterogeneous  nature  of
the  necrotic  tissue)  and  the  other  percutaneously  (important
spread).  In  both  cases,  the  outcome  was  favorable.The  mean  size  of  necrotic  RAMLs  was  11  cm  (7—16  cm)
before  treatment  and  16  cm  (9—27  cm)  at  the  onset  of  necro-
sis.  The  lesions  were  surrounded  by  a  thick  capsule  with  a
mean  width  of  10  mm  (6—15  mm).
h
t
l
Figure 2. a: early phase angiography of a large RAML in the lower p
contrast-enhanced CT scan in the axial plane obtained during the arteria
post-embolization (coils and microspheres) tumor necrosis. Fatty ﬂuid la
intravenous administration of gadolinium chelate during the nephrogra
embolization with coils and microspheres of a large, high fat content RAM
cavities (black arrow) by compression of the renal pelvis by the necrotic
pole of right kidney following arterial embolization with coils and microomyolipomas  583
Subsequent  to  necrosis  and  the  inﬂammatory  reaction,
he  mean  reduction  in  size  of  necrotic  lesions  was  of  81%
post-drainage  for  two  lesions)  with  a mean  size  of  4  cm
1.5—9  cm).
Other  events  were  also  observed  in  the  necrosis  group:
ipiduria  (n  =  3)  was  observed  in  three  patients  and  two
atients  showed  systemic  inﬂammatory  disease  (one  case
f  rheumatoid  purpura  several  months  after  embolization
nd  one  case  of  inﬂammatory-like  joint  pain  one  year  after
mbolization).  However  the  relationship  between  these
linical  manifestations  and  the  onset  of  necrosis  was  not
ully  established.
omparison of the necrosis and non-necrosis
ub-groups
ll  the  patients  in  the  sub-group  with  post  embolization
ecrosis  (n  =  6)  were  women;  themean  age  was  41.5  years
25—54  years)  (Tables  1—3).  Two  patients  from  this  sub-group
ad  tuberous  sclerosis  complex.
Arterial  dysplasia  was  observed  in  all  of  the  lesions  of
he  necrosis  sub-group  (100%)  and  in  79%  of  non-necrotic
esions.
ole of a right kidney showing arterial dysplasia (white arrow); b:
l phase of a large RAML in the lower pole of a right kidney showing
yer (white arrow); c: fat-suppressed T1-weighted MR image after
phic phase shows RAML necrosis (white arrow) following arterial
L in the lower pole of a right kidney. Dilatation of the pelvicalyceal
 RAML; d: CT-guided drainage of large necrotic RAML in the lower
spheres.
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There  was  a  signiﬁcant  difference  between  the  mean  ini-
ial  volume  of  the  RAML  in  the  necrosis  sub-group  (331  cm3)
nd  the  sub-group  without  tumor  necrosis  (88  cm3),  as  deter-
ined  by  the  Wilcoxon  test  (P  =  0.0047)  (Fig.  4).
High  fat  content  RAMLs  were  more  frequent  in  the  necro-
is  sub-group  (6/6  patients,  100%)  than  in  the  sub-group
ithout  tumor  necrosis  (18/24,  75%).
The  mean  post-embolization  volume  was  43  ±  41  cm3 for
on-necrotic  RAMLs  and  30  ±  61  cm3 for  necrotic  RAMLs,
lthough  the  difference  between  the  two  sub-groups  was
ot  signiﬁcant  (P  =  0.146).  The  mean  reduction  in  tumor
olume  was  68%  and  37%  for  patients  treated  with  a  com-
ination  of  microspheres  and  coils  (n  =  18)  and  coils  alone
n  =  8),  respectively.  The  results  were  variable  for  patients
mbolized  with  microspheres  alone  (n  =  4).
The  reduction  in  tumor  volume  was  therefore  greater  in
he  group  embolized  with  coils  and  microspheres  (68%)  than
n  the  group  embolized  with  coils  alone  (37%).  However  no
ases  of  necrosis  were  observed  in  the  group  embolized  with
oils  alone.
d
s
a
igure 3. a: contrast-enhanced CT scan in the axial plane obtained d
white arrow); b: early phase renal angiography of large RAML in the low
arly phase renal angiography: embolization with coils and microsphere
nhanced CT scan in the nephrographic phase shows RAML necrosis follow
rterial dysplasia and a fatty ﬂuid layer (white arrow); e: contrast-enhan
2 months after arterial embolization (white arrow).M.  El  Rafei  et  al.
The  mean  reduction  in  tumor  volume  (%)  in  the  overall
atient  population  was  60%  (ranging  from  0  to  100%).  The
eduction  in  tumor  volume  differed  between  the  sub-groups
ith  low  fat  content  RAMLs  (36%)  and  high  fat  content  AMLs
65%).  In  the  sub-group  with  high  fat  content  RAMLs,  this
ercentage  was  found  to  vary  again  depending  on  whether
he  RAML  became  necrotic  (81%)  or  not  (57%).
The  other  post-embolization  complications  reported  in
able  3  (arterial  hypertension,  localized  infarction)  were  not
ssociated  with  tumor  necrosis.
iscussion
lthough  its  histopathological  features  are  benign,  17—20%
f  all  cases  of  peripheral  bleeding  are  due  to  the  rupture  of
ilated  blood  vessels  in  RAML  [12].
The  risk  of  RAML  bleeding  complications  depends  on
everal  factors  such  as  AML  size  (>  4  cm),  intratumoral
rterial  aneurysms  with  diameters  >  4  mm,  intratumoral
uring the arterial phase shows large RAML with arterial dysplasia
er pole of a right kidney with arterial dysplasia (white arrow); c:
s of large RAML with arterial dysplasia (black arrow); d: contrast-
ing embolization with coils and microspheres of a large RAML with
ced CT scan in the axial plane shows 90% reduction in RAML volume
Tumor  necrosis  after  preventive  embolization  of  large  renal  angi
Figure 4. Distribution of calculated AML volume in both sub-
groups (blue: without necrosis; green: with necrosis) prior to
treatment (position 1) and after treatment (position 2). Signiﬁcant
difference in tumor volume prior to treatment between the sub-
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tumors  sized  >  10  cm  [31].groups (with and without necrosis) (P = 0.0047). The difference in
volume is no longer signiﬁcant after treatment (P = 0.1460).
arterial  dysplasia,  multifocal  vessel  anomalies,  high-risk
locations  (subcapsular  or  exorenal  locations),  a  history  of
bleeding  and  the  hormonal  setting  (pregnancy,  childbirth)
[7,11,13,22,23].
Preventive  embolization  has  recently  been  added
to  the  latest  recommendations  for  RAML  management
[14,15].
Our  study  was  based  on  a  patient  population  who  under-
went  preventive  embolization  only.  Due  to  the  optimal
conditions  in  which  these  procedures  were  carried  out
and  their  selective  nature,  the  technical  and  clinical  suc-
cess  rates  achieved  were  of  97%  and  87%  respectively  with
patients  rarely  in  need  of  subsequent  embolization  (13%),
which  is  in  line  with  previous  reports  [7,12,18,24,25].
The  average  reduction  in  tumor  volume  was  60%  after
an  average  follow-up  of  42  months.  In  previous  studies,  this
reduction  in  volume  was  reported  to  range  from  23  to  70%
depending  on  the  duration  of  the  follow-up  period  [18,26].
We  noted  a  mean  post-embolization  reduction  of  65%  in
the  volume  of  high  fat  content  RAMLs  compared  to  36%  in
low  fat  content  RAMLs  (overall  population).  Our  results  are
different  from  those  reported  by  Han  et  al.  and  Hocquelet
et  al.  who  described  the  reduction  in  volume  as  being  associ-
ated  with  angiomyomatous  tissue  [26,27].  This  discrepancy
could  be  explained  by  less  arteriovenous  shunting  in  high
fat  content  AMLs  which  leads  to  more  efﬁcient  emboliza-
tion.  It  could  also  be  due  to  ﬁner  vascular  network  found
in  adipose  tissue  that  could  increase  the  risk  of  necrosis.
However,  further  investigations  are  required  to  conﬁrm  such
hypotheses.We  observed  that  the  reduction  in  volume  was  greater
in  patients  treated  with  a  combination  of  microspheres  and
coils  (68%  vs.  37%  with  coils  alone).
t
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Different  embolic  agents  have  been  described  in  the
iterature  such  as  polyvinyl  alcohol  particles,  ethanol,
icrospheres,  gelfoam  and  coils  [10,17,18].  However,  pre-
ious  studies  using  the  same  embolic  agents  as  used  here
i.e.  microspheres  and  coils)  did  not  assess  the  complications
bserved  for  each  embolic  agent  [10,17,18]. Recent  guide-
ines  recommend  the  use  of  microspheres  with  a  diameter
f  more  than  500  m  to  avoid  leakage  through  intratumoral
rteriovenous  shunts  [14,15,28].
Six  cases  of  post-embolization  tumor  necrosis  led  us  to
earch  for  factors  that  predispose  to  this  complication  by
omparing  the  sub-groups  with  and  without  necrosis.  This
omplication,  which  shows  a  unique  imaging  signature,  is
arely  described  in  the  literature  but  has  important  clin-
cal  and  biological  consequences  and  can  require  surgical
rainage.  We  identiﬁed  the  following  predisposing  factors:
initial  tumor  volume:  in  our  population,  necrosis  was
observed  in  much  larger  tumors.  The  signiﬁcant  differ-
ence  seen  in  tumor  size  reduction  (P  =  0.0043)  is  thus
related  to  the  initial  volume  of  the  RAML;
fat  content:  all  necrotic  RAMLs  had  a high  fat  content
(>  50%).  However  19  non-necrotic  RAMLs  also  had  a  high
fat  content  so,  due  to  the  limited  number  of  patients
included,  it  is  difﬁcult  to  demonstrate  a  statistical  rela-
tionship  between  the  fat  content  and  the  onset  of
necrosis;
arterial  dysplasia:  all  necrotic  RAMLs  displayed  arterial
dysplasia  (Fig.  4);
embolic  agents:  in  both  of  the  sub-groups  in  our
population,  RAML  embolization  was  performed  using
microspheres,  coils  or  a combination  of  both.  However,
all  patients  with  necrotic  RAMLs  had  undergone  at  least
one  distal  embolization  using  microspheres.  Due  to  the
limited  number  of  patients,  the  sub-group  treated  with
microspheres  alone  could  not  be  compared  statistically
to  the  sub-group  embolized  with  coils  alone.  However,
our  results  suggest  a  relationship  between  microspheres
and  tumor  necrosis,  even  if  it  could  not  be  demonstrated
statistically.
Recent  guidelines  on  the  embolization  of  RAMLs  in
atients  with  TSC  and  uterine  ﬁbroids  recommend  that  distal
mbolization  using  microspheres  should  be  followed  by  prox-
mal  vessel  occlusion  with  coils  to  achieve  optimal  efﬁcacy
14,15,29].
In  our  patient  population,  microspheres  (>  500  m)  were
sed  as  the  embolic  agent  for  17  of  the  22  (74%)  emboliza-
ions  performed.  In  ﬁve  of  the  six  cases  with  necrotic
AMLs,  embolization  had  been  performed  with  microspheres
f  diameter  >  500  m;  in  the  remaining  case,  microspheres
f  300—500  m  had  been  used.  Pelage  et  al.  [29]  demon-
trated  that  the  risk  of  post-embolization  uterine  necrosis
as  greater  when  small  microspheres  (<500—600  m)  were
sed  due  to  distal  artery  occlusion.  This  risk  was  higher
or  tumors  sized  >  10  cm  [30].  With  regards  to  uterine
broid  embolization,  Trillaud  recommended  using  free-ﬂow
mbolization  with  calibrated  microspheres,  in  particular  forIn  our  study,  the  decision  to  perform  arterial  emboliza-
ion  for  RAML  was  taken  after  discussion  by  a  multidisci-
linary  team  of  specialists  (urologists  and  radiologists).  This
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s  consistent  with  the  management  of  other  conditions  that
equire  arterial  embolization  [32,33].
The  main  limitation  of  this  retrospective  study  is  the  low
umber  of  necrotic  lesions.  A  greater  number  of  necrotic
ases  would  have  allowed  for  discriminant  statistical  analy-
is  based  on  the  fat  content  or  the  embolic  agents  used.
However,  our  data  suggest  that  necrosis  occurs  more
requently  after  the  distal  embolization  with  microspheres
f  large,  high  fat  content  RAMLs.  Further  investigation  is
equired  to  conﬁrm  this  hypothesis  via  multicenter  studies
ncluding  larger  numbers  of  patients.
onclusion
umor  necrosis  following  RAML  arterial  embolization  is  an
nderestimated  complication  that  can  require  surgical  or
ercutaneous  drainage.  It  seems  to  occur  predominantly
n  large,  high  fat  content  (>50%)  tumors  treated  by  dis-
al  embolization  with  microspheres  (associated  or  not  with
roximal  embolization  with  coils).
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